Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults

被引:74
作者
Giustina, A. [1 ]
Barkan, A. [2 ]
Chanson, P. [3 ,4 ,5 ]
Grossman, A. [6 ]
Hoffman, A. [7 ]
Ghigo, E. [8 ]
Casanueva, F. [9 ,10 ]
Colao, A. [11 ]
Lamberts, S. [12 ]
Sheppard, M. [13 ]
Melmed, S. [14 ]
机构
[1] Univ Brescia, Dept Internal Med, Brescia, Italy
[2] Univ Michigan, Med Ctr, Div Endocrinol & Metab, Ann Arbor, MI USA
[3] Bicetre Hosp, Dept Endocrinol, Le Kremlin Bicetre, France
[4] Bicetre Hosp, Dept Reprod Dis, Le Kremlin Bicetre, France
[5] Univ Paris 11, Le Kremlin Bicetre, France
[6] Queen Mary Univ, Barts & London Sch Med, St Bartholomews Hosp, Dept Endocrinol, London, England
[7] Stanford Univ, Dept Endocrinol Gerontol & Metab, Stanford, CA 94305 USA
[8] Univ Turin, Dept Internal Med, Div Endocrinol, Turin, Italy
[9] Dept Med, Div Endocrinol, Santiago De Compostela, Spain
[10] Complejo Hosp Santiago, Santiago De Compostela, Spain
[11] Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, Naples, Italy
[12] Erasmus MC, Dept Med, Rotterdam, Netherlands
[13] Univ Birmingham Edgbaston, Sch Med, Birmingham, W Midlands, England
[14] Cedars Sinai Med Ctr, Dept Endocrinol, Los Angeles, CA 90048 USA
关键词
Acromegaly; growth hormone deficiency; growth hormone replacement; somatostatin analogs; treatment recommendations;
D O I
10.1007/BF03349263
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The V Consensus Group Meeting on 'Guidelines for Treatment of GH Excess and GH Deficiency in the Adult' was an international workshop held on February 20-22, 2006 in Santa Monica, California, USA. The principal aim of this meeting was to provide guidelines for the evaluation and treatment of adults with either form of abnormal GH secretion: GH excess or GH deficiency. The workshop included debates as to the choice of primary treatment, discussions of the targets for adequate treatment, and concluded with presentations on open issues germane to adult GH treatment including the role of GH in malignancies, the impact of long-term treatment on bone, and a cost-benefit analysis. The meeting was comprised of 66 delegates representing 13 different countries.
引用
收藏
页码:820 / 838
页数:19
相关论文
共 173 条
[1]  
*AACE ACR GUID TAS, 2004, ENDOCR PRACT, V10, P213
[2]   Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre [J].
Abe, T ;
Lüdecke, DK .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2001, 145 (02) :137-145
[3]   Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initial outcome and long-term results [J].
Abosch, A ;
Tyrrell, JB ;
Lamborn, KR ;
Hannegan, LT ;
Applebury, CB ;
Wilson, CB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (10) :3411-3418
[4]   Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients [J].
Agha, Amar ;
Walker, Dorothy ;
Perry, Les ;
Drake, William M. ;
Chew, Shern L. ;
Jenkins, Paul J. ;
Grossman, Ashley B. ;
Monson, John P. .
CLINICAL ENDOCRINOLOGY, 2007, 66 (01) :72-77
[5]  
Ahmed S, 1999, CLIN ENDOCRINOL, V50, P561
[6]   EPIDEMIOLOGY OF ACROMEGALY IN THE NEWCASTLE REGION [J].
ALEXANDER, L ;
APPLETON, D ;
HALL, R ;
ROSS, WM ;
WILKINSON, R .
CLINICAL ENDOCRINOLOGY, 1980, 12 (01) :71-79
[7]   Efficacy and tolerability of lanreotide autogel therapy in acromegalic patients previously treated with octreotide LAR [J].
Alexopoulou, O ;
Abrams, P ;
Verhelst, J ;
Poppe, K ;
Velkeniers, B ;
Abs, R ;
Maiter, D .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 151 (03) :317-324
[8]   Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly [J].
Amato, G ;
Mazziotti, G ;
Rotondi, M ;
Iorio, S ;
Doga, M ;
Sorvillo, F ;
Manganella, G ;
Di Salle, F ;
Giustina, A ;
Carella, C .
CLINICAL ENDOCRINOLOGY, 2002, 56 (01) :65-71
[9]  
[Anonymous], WILLIAMS TXB ENDOCRI
[10]   Diagnostic value of the acid-labile subunit in acromegaly: Evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3 [J].
Arosio, M ;
Garrone, S ;
Bruzzi, P ;
Faglia, G ;
Minuto, F ;
Barreca, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (03) :1091-1098